Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BD to Unveil New IV Chemotherapy Administration Digital Solution at EAHP 2018

Posted on: 20 Mar 18

Company to Hold Medication Safety Symposium Today at 14:30 in Room G4

Gothenburg, Sweden, March 21 2018 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will introduce its latest advancement in end-to-end IV safety, the new BD Cato™ ReadyMed solution — a digital solution that integrates with BD Cato™, designed to help hospitals optimize the IV chemotherapy administration process by simplifying workflows and providing medication visibility with the ability to track the medication’s journey to the patient.


The company is making the announcement at the 23rd Congress of the European Association of Hospital Pharmacists (EAHP) being held in Gothenburg, Sweden from March 21-23. At the BD booth (#65), the company will explain its comprehensive medication management strategy and showcase its solutions to improve both safety and efficiency at every step, from prescription, preparation, dispensing to administration. Within the comprehensive approach to integrated, enterprise medication management across the continuum of care, BD demonstrates its new BD Cato ReadyMed solution, which features:

•      A simple and intuitive barcoded medication administration (BCMA) documentation, checking and tracking program that ensures safe medication is given;

•      A more efficient way for health care workers to administer IV chemotherapy by cutting the number of steps in half compared to current workflow;

•      The ability for hospitals to achieve a HIMSS Europe level 6 adoption and utilization of electronic medical records (EMR) functions required to achieve a paperless environment.


“We are constantly working to identify new solutions to help making things safer for patients,” said Christian Hanke, Founder of Cato software and Director of Strategic Innovations for Pyxis Medication Technologies at BD. “After supporting safety in prescribing, pharmacy checking and cleanroom workflow, adding a mobile technology to ensure bedside administration verification was the next logical step. Medication errors have to be caught directly where they may occur.”

According to a recent study published in the UK by the Policy Research Unit in Economic Evaluation of Health & Care Interventions (EEPRU)[1], an estimated 66 million potentially clinically significant medication errors occur per year in the UK alone with 71 percent of these in primary care.  In addition, the estimated NHS costs of avoidable adverse drug reactions (ADRs) are £98.5 million per year, consuming 181,626 bed-days, causing 712 deaths, and contributing to 1,708 deaths.


“As research indicates, medication errors have a detrimental impact on patient safety, clinical outcomes and institutional efficiency,” said Roland Goette, EVP and president of BD Europe, Middle East and Africa. “BD recognizes that a proactive, integrated and systematic approach to medication management is essential to achieving healthcare systems’ goals to reduce medication errors and improve patient safety. As part of our purpose of advancing the world of health, we are committed to helping healthcare systems, institutions and clinicians reduce medication errors, which today represent a health and safety issue for providers and patients. We partner with our customers to reduce medication errors by supporting their ongoing efforts to develop a culture of safety through safe, innovative and optimized solutions that impact multiple stages of the medication management process.”


Considering these alarming statics, BD will hold a special symposium during EAHP on

Wednesday, March 21 from 14:30 to 16:00 in room G4 to cover a variety of pressing topics throughout the medication management process, including:

•      Dr. Silvia Valero – La Fe Hospital, Valencia, Spain will be speaking on security and efficiency of Close System Transfer Devices (CSTDs) 

•      Warren Poon – Leader in Oncology Care, London, UK will be addressing “The adoption of the new IV workflow compounding system maximizes the safety and efficiency in the LOC

•      Dr. Olivier Aujoulat, Mulhouse Hospital in France will focus on “Organizational and safety impact of automated pharmacy solutions” with a proven case-study on how automation at their hospital has reduced dispensing errors dramatically, with expected savings of €443,000 over a 15-years period

•      Dr. Sara Arenas-Lopez – Evelina London Children’s Hospital, Guy’s & St. Thomas’ NHS Foundation Trust, UK will speak on “Safe implementation of standard concentration of infusions in a pediatric intensive care unit”


To learn more about BD’s presence at EAHP 2018 visit and be sure to visit the BD booth #65 to experience the difference of the company’s comprehensive medication management solutions across the care continuum.


About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit

Editor's Details

Mike Wood

Last updated on: 20/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.